IRIS
LO CAPUTO, Sergio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.908
AS - Asia 2.844
NA - Nord America 2.251
SA - Sud America 934
AF - Africa 77
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 9.019
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.152
SG - Singapore 1.431
IE - Irlanda 1.005
BR - Brasile 799
RU - Federazione Russa 528
HK - Hong Kong 491
CN - Cina 394
SE - Svezia 292
DE - Germania 273
IT - Italia 273
VN - Vietnam 267
UA - Ucraina 125
FI - Finlandia 117
GB - Regno Unito 82
AT - Austria 49
AR - Argentina 48
FR - Francia 41
CA - Canada 39
MX - Messico 37
IQ - Iraq 36
BD - Bangladesh 34
TR - Turchia 34
IN - India 29
NL - Olanda 26
ZA - Sudafrica 24
VE - Venezuela 22
ES - Italia 19
EC - Ecuador 18
CZ - Repubblica Ceca 16
UZ - Uzbekistan 16
JP - Giappone 15
PK - Pakistan 14
BE - Belgio 13
CO - Colombia 12
ID - Indonesia 12
PL - Polonia 12
PY - Paraguay 12
LT - Lituania 11
AZ - Azerbaigian 8
IR - Iran 8
KE - Kenya 8
NP - Nepal 8
PE - Perù 8
AE - Emirati Arabi Uniti 7
CL - Cile 7
DZ - Algeria 7
MA - Marocco 7
DO - Repubblica Dominicana 6
TN - Tunisia 6
EG - Egitto 5
NG - Nigeria 5
SA - Arabia Saudita 5
BO - Bolivia 4
ET - Etiopia 4
OM - Oman 4
PA - Panama 4
QA - Qatar 4
RS - Serbia 4
SK - Slovacchia (Repubblica Slovacca) 4
UY - Uruguay 4
AL - Albania 3
AM - Armenia 3
AU - Australia 3
JM - Giamaica 3
JO - Giordania 3
KR - Corea 3
KZ - Kazakistan 3
MY - Malesia 3
PH - Filippine 3
BB - Barbados 2
BF - Burkina Faso 2
CH - Svizzera 2
CR - Costa Rica 2
GT - Guatemala 2
HU - Ungheria 2
TL - Timor Orientale 2
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BY - Bielorussia 1
CG - Congo 1
CI - Costa d'Avorio 1
DK - Danimarca 1
EU - Europa 1
GR - Grecia 1
HN - Honduras 1
IS - Islanda 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
MU - Mauritius 1
NA - Namibia 1
NE - Niger 1
NO - Norvegia 1
PR - Porto Rico 1
PS - Palestinian Territory 1
Totale 9.010
Salva come PNG Salva come JPEG
Città #
Dublin 1.004
Singapore 551
Hong Kong 488
Ashburn 281
Santa Clara 229
Nyköping 208
Dallas 189
Chandler 165
Munich 162
Beijing 157
Moscow 125
Princeton 116
Helsinki 91
Los Angeles 91
Ho Chi Minh City 86
Wilmington 73
São Paulo 64
New York 61
Hanoi 43
The Dalles 37
Dong Ket 34
Nuremberg 34
Des Moines 33
Assago 32
Rio de Janeiro 32
Bari 29
London 25
Boardman 24
Dearborn 24
Jacksonville 23
Frankfurt am Main 22
San Francisco 20
Vienna 19
Brasília 17
Brooklyn 17
Düsseldorf 17
Nanjing 17
Shanghai 17
Baghdad 16
Falkenstein 16
Belo Horizonte 15
Boston 15
Johannesburg 15
Tashkent 15
Tokyo 15
Council Bluffs 14
Gioia Del Colle 14
Washington 14
Stockholm 13
Brussels 12
Da Nang 12
Turku 12
Brno 11
Campinas 11
Chicago 11
Guangzhou 11
Warsaw 11
Atlanta 10
Columbus 10
Curitiba 10
Norwalk 10
Salvador 10
St Louis 10
Toronto 10
Chennai 9
Maceió 9
Porto Alegre 9
Baku 8
Denver 8
Goiânia 8
Istanbul 8
Montreal 8
Phoenix 8
Wuhan 8
Ankara 7
Canoas 7
Caxias do Sul 7
Foggia 7
Guayaquil 7
Jyväskylä 7
Ninh Bình 7
Ann Arbor 6
Caracas 6
Erbil 6
Franca 6
Joinville 6
Mexico City 6
Milan 6
Nairobi 6
Osasco 6
Ottawa 6
Ribeirão Preto 6
San Mateo 6
Santa Maria 6
Seattle 6
São José 6
Uberlândia 6
Amsterdam 5
Borås 5
Buenos Aires 5
Totale 5.223
Salva come PNG Salva come JPEG
Nome #
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 176
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 149
Tocilizumab and corticosteroids for covid-19 treatment in elderly patients. Journal of Gerontology and Geriatrics 103
Real Time PCR and Culture-Based Virus Isolation Test in Clinically Recovered Patients: Is the Subject Still Infectious for SARS-CoV2? 101
Efficacy and Safety of Remdesivir over Two Waves of the Sars-CoV-2 Pandemic 101
Estimating minimum adult HIV prevalence: a cross-sectional study to assess the characteristics of people living with HIV in Italy. 96
2Apolipoprotein B mRNA–Editing Enzyme, Catalytic Polypeptide–Like 3G: A PossibleRole in the Resistance to HIV of HIV-1 Exposed Seronegative Individuals 96
Peculiar clinical presentation of COVID-19 and predictors of mortality in the elderly: A multicentre retrospective cohort study 92
Monitoraggio virologico in soggetti con infezione da HIV in trattamento con Zidovudina (AZT) 90
Long-term failure of antiviral activity of Zidovudine therapy in anti-HIV positive subjects 86
Prevalence of hepatitis virus infections in Albanian refugees. 85
Sex and gender differences in COVID-19: an Italian local register- based study 79
Baricitinib: A chance to treat COVID-19? 75
Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patients 75
96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience 75
Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): Data from a real-life setting 74
Two nasal swabs may not be enough to exclude SARS-CoV-2 infection in symptomatic patients 72
Percorsi di vaccinazione anti-Herpes Zoster nel paziente fragile: proposte dagli specialisti del Policlinico Foggia 71
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 71
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment 70
Influence of Gender, Age, and Transmission Category on the Progression From HIV Seroconversion to AIDS 70
Identification of a Specific miRNA Profile in HIV-Exposed Seronegative Individuals 69
Comparison between Rules-Based Human Immunodeficiency Virus Type 1 Genotype Interpretations and Real or Virtual Phenotype: Concordance Analysis and Correlation with Clinical Outcome in Heavily Treated Patients 68
HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations 67
A common polymorphism in TLR3 confers natural resistance to HIV-1 infection 66
Anti-nef antibodies and other predictors of disease progression in HIV-1 seropositive injecting drug users 66
Interleukin 21 (IL-21)/microRNA-29 (miR-29) axis is associated with natural resistance to HIV-1 infection 66
A comprehensive development agenda on tenofovir alafenamide in clinical practice 66
Twenty Years Later: the Recent Trends of HIV-infection – Evidence from an Italian Region 65
Pregnancy Outcomes Among ART-Naive and ART-Experienced HIV-Positive Women: Data From the ICONA Foundation Study Group, Years 1997–2013 65
Resistance to Dideoxynucleoside Reverse Transcriptase Inhibitors: Genotypic-Phenotypic Correlations 65
Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress? 65
Safety and heart rate changes in Covid-19 patients treated with Remdesivir 65
Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection 63
. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. 63
A 6-amino acid insertion/deletion polymorphism in the mucin domain of TIM-1 confers protections against HIV-1 infection 63
A positively selected APOBEC3H haplotype is associated with natural resistance to HIV-1 infection 63
IL-22 Participates in an Innate Anti-HIV-1 Host-Resistance Network through Acute-Phase Protein Induction 62
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 62
Self-Reported Symptoms and Medication Side Effects Influence Adherence to Highly Active Antiretroviral Therapy in Persons With HIV Infection 61
Lost to follow-up: a challenge over 10 years 61
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 61
The Onset of Antinuclear Antibodies (ANAs) as a Potential Risk Factor for Mortality and Morbidity in COVID-19 Patients: A Single-Center Retrospective Study 60
Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Non-AIDS-Defining Events in a Large Cohort of HIV-Infected Patients 60
HIV rapid test in a community setting as a strategy to improve access to HIV testing: Data from a multicentre experience in Italy 60
Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients - evidence from a large observational cohort 60
Monkeypox virus infection mimicking primary syphilis 59
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort 59
Efficacy and Safety of Remdesivir over Two Waves of the SARS-CoV-2 Pandemic 58
Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort 58
An intricate case of multidrug resistant Plasmodium falciparum isolate imported from Cambodia. 58
Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts 58
Evaluation of the effect of protective genetic variants on cart success in hiv-1-infected patients 57
Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev 56
Low Prevalence of Antibodies to SARS-CoV-2 and Undetectable Viral Load in Seropositive Blood Donors from South-Eastern Italy 56
Marked decrease in acquired resistance to antiretrovirals in latest years in Italy 56
A Randomized Controlled Trial to Evaluate Antiretroviral Salvage Therapy Guided by Rules-Based or Phenotype-Driven HIV-1 Genotypic Drug-Resistance Interpretation With or Without Concentration-Controlled Intervention: The Resistance and Dosage Adapted Regimens (RADAR) Study 55
A role for mucosal immunity in resistance to HIV infection 55
. Reduced community viral load does not coincide with a reduction in the rate of new HIV diagnoses and recent infections: data from a region of southern Italy 54
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 54
Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy 52
Distinct patterns of HIV-specific memory T lymphocytes in HIV-exposed uninfected individuals and in HIV-infected patients 52
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 52
An evolutionary analysis of antigen processing and presentation across different timescales reveals pervasive selection. 51
Italian Consensus Statement on Management of HIV-Infected Individuals with Advanced Disease Naïve to Antiretroviral Therapy 51
Correlation between seroreactivity to HIV-1 V3 loop peptides and male-to-female heterosexual transmission 51
Difficulties in classifying a/g recombinants: methodological problems or genetic variability? 51
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 50
Severity of covid‐19 patients predicted by serum sphingolipids signature 50
Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with Discontinuation 49
Influence of Genotype 3 Hepatitis C Coinfection on Liver Enzyme Elevation in HIV-1-Positive Patients After Commencement of a New Highly Active Antiretroviral Regimen: Results From the EPOKA-MASTER Cohort 49
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 49
Neuropsychiatric Disorders in Pediatric Long COVID-19: A Case Series 48
Decrease in Incidence Rate of Hospitalizations Due to AIDS-Defining Conditions but Not to Non-AIDS Conditions in PLWHIV on cART in 2008-2018 in Italy 48
Toll-like receptor activation pathways in HIV-1 exposed seronegative individuals 48
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort) 48
RADAR Study Group of MASTER Cohort “Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients 48
Peculiar clinical presentation of COVID-19 and predictors of mortality in the elderly: A multicentre retrospective cohort study 47
The elderly and direct antiviral agents: Constraint or challenge? 47
Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: Prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients 47
Risk of Developing Specific AIDS”Defining Illnesses in Patients Coinfected with HIV and Hepatitis C Virus With or Without Liver Cirrhosis 47
Endoplasmic reticulum aminopeptidase 2 haplotypes ply a role in modulating susceptibility to HIV infection 46
Characterization of viro-immunological responses in a closely followed cohort of heavily pretreated patients: evidence from the GenPheRex Study 46
Prevalence of hepatitis virus infections in Albanian refugees 46
Doravirine Plus Integrase Strand Transfer Inhibitors as a 2-Drug Treatment–Switch Strategy in People Living with HIV: The Real-Life DORINI Multicentric Cohort Study 45
PrEP in Italy: The time may be ripe but who's paying the bill? A nationwide survey on physicians' attitudes towards using antiretrovirals to prevent HIV infection 45
Genotypes at chromosome 22q12-13 are associated with HIV-1-exposed but uninfected status in Italians 45
Mucosal and Systemic Immune Activation Is Present in Human Immunodeficiency Virus–Exposed Seronegative Women 45
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure 44
Prevalence and genetic diversity of Blastocystis sp. among autochthonous and immigrant patients in Italy 44
Prevalence and genetic diversity of Blastocystis sp. among autochthonous and immigrant patients in Italy 44
Assessing ChatGPT's Potential in HIV Prevention Communication: A Comprehensive Evaluation of Accuracy, Completeness, and Inclusivity 44
Long-Term Effectiveness of Rilpivirine-Based Single-Tablet Regimens in a Seven-Year, Two-Center Observational Cohort of People Living with HIV 44
Variants in the CYP7B1 gene region do not affect natural resistance to HIV-1 infection 44
Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing 44
Specific Enfuvirtide Associated Mutational Pathways in HIV-1 Gp41 Are Significantly Correlated With an Increase in CD4+ Cell Count, Despite Virological Failure 44
Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients 44
The mucosae-associated epithelial chemokine (MEC/CCL28) modulates immunity in HIV infection 43
Evolutionary analysis identifies an MX2 haplotype associated with natural resistance to HIV-1 infection 43
A Comprehensive Development Agenda on Tenofovir Alafenamide in Clinical Practice 42
Totale 6.169
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.481
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.481
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021455 0 0 0 0 0 2 6 2 266 91 11 77
2021/2022492 81 3 3 15 30 26 12 50 63 36 24 149
2022/20231.805 164 27 90 36 35 117 12 62 1.116 94 28 24
2023/2024558 68 34 28 16 30 96 65 12 108 21 9 71
2024/20253.546 196 64 69 66 64 390 669 218 1.013 188 252 357
2025/20262.746 334 430 670 872 280 160 0 0 0 0 0 0
Totale 9.744